JP2024543918A5 - - Google Patents

Info

Publication number
JP2024543918A5
JP2024543918A5 JP2024531366A JP2024531366A JP2024543918A5 JP 2024543918 A5 JP2024543918 A5 JP 2024543918A5 JP 2024531366 A JP2024531366 A JP 2024531366A JP 2024531366 A JP2024531366 A JP 2024531366A JP 2024543918 A5 JP2024543918 A5 JP 2024543918A5
Authority
JP
Japan
Prior art keywords
polynucleotide
sequence
polya
promoter
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543918A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/134993 external-priority patent/WO2023093905A1/zh
Publication of JP2024543918A publication Critical patent/JP2024543918A/ja
Publication of JP2024543918A5 publication Critical patent/JP2024543918A5/ja
Pending legal-status Critical Current

Links

JP2024531366A 2021-11-29 2022-11-29 Aadc、gdnfポリヌクレオチド及びそのパーキンソン病を治療するための使用 Pending JP2024543918A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111434384 2021-11-29
CN202111434384.4 2021-11-29
PCT/CN2022/134993 WO2023093905A1 (zh) 2021-11-29 2022-11-29 Aadc、gdnf多核苷酸及其用于治疗帕金森病

Publications (2)

Publication Number Publication Date
JP2024543918A JP2024543918A (ja) 2024-11-26
JP2024543918A5 true JP2024543918A5 (cg-RX-API-DMAC7.html) 2025-12-10

Family

ID=86538881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531366A Pending JP2024543918A (ja) 2021-11-29 2022-11-29 Aadc、gdnfポリヌクレオチド及びそのパーキンソン病を治療するための使用

Country Status (9)

Country Link
US (1) US20250051750A1 (cg-RX-API-DMAC7.html)
EP (1) EP4442830A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024543918A (cg-RX-API-DMAC7.html)
KR (1) KR20240110849A (cg-RX-API-DMAC7.html)
CN (1) CN118525098A (cg-RX-API-DMAC7.html)
AU (1) AU2022397707A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238867A1 (cg-RX-API-DMAC7.html)
TW (1) TW202325850A (cg-RX-API-DMAC7.html)
WO (1) WO2023093905A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025516136A (ja) * 2022-04-19 2025-05-27 シャンハイ ヴァイタルゲン バイオファーマ カンパニー リミテッド 神経変性疾患の治療のための組み換えaavベクター
CN118252953A (zh) * 2022-12-26 2024-06-28 科辉智药(深圳)新药研究中心有限公司 一种用于神经退行性疾病治疗的基因序列构建体及其应用
TW202508610A (zh) 2023-08-23 2025-03-01 大陸商上海瑞宏迪醫藥有限公司 醫藥組成物及其用途
WO2025060451A1 (zh) * 2023-09-18 2025-03-27 上海金珂博生物技术有限公司 经修饰的腺相关病毒载体及其在治疗神经疾病中的用途
CN117904201B (zh) * 2023-10-19 2026-03-27 广州逐鹿生物科技有限公司 一种用于清除乙肝病毒的病毒基因治疗载体及应用
US20250333807A1 (en) * 2024-04-29 2025-10-30 Agathos Biologics Recombinant Adeno-Associated Virus (rAAV) Universal Reference Standard for Determining rAAV Genome Copy Titer by Quantitative PCR

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006116A1 (en) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5865744A (en) 1996-09-16 1999-02-02 Lemelson; Jerome H. Method and system for delivering therapeutic agents
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
WO2001023001A2 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
EP1463805B1 (en) 2001-12-17 2014-10-22 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
WO2006063247A2 (en) * 2004-12-09 2006-06-15 Genzyme Corporation Regulated expression of transgenes in the central nervous system of mammals
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
EP2158211B1 (en) 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
WO2009067205A1 (en) 2007-11-21 2009-05-28 Surgi-Vision, Inc. Methods, systems and computer program products for positioning a guidance apparatus relative to a patient
EP2910637A1 (en) 2008-05-20 2015-08-26 University of Florida Research Foundation, Inc. Vectors for delivery of light-sensitive proteins and methods of use
JP5559185B2 (ja) * 2008-11-11 2014-07-23 オックスフォード バイオメディカ(ユーケー)リミテッド 方法
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US9546112B2 (en) 2010-03-22 2017-01-17 Association Institut De Myologie Methods of increasing efficiency of vector penetration of target tissue
DK2561073T3 (en) 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
US10738326B2 (en) 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
US20140359799A1 (en) 2011-12-23 2014-12-04 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
BR112014020325A2 (pt) 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
PL2900686T3 (pl) 2012-09-28 2021-01-25 The University Of North Carolina At Chapel Hill Wektory aav ukierunkowane na oligodendrocyty
WO2014124282A1 (en) 2013-02-08 2014-08-14 The Trustees Of The University Of Pennsylvania Enhanced aav-mediated gene transfer for retinal therapies
ES2926774T3 (es) 2013-03-15 2022-10-28 Univ North Carolina Chapel Hill Métodos y composiciones para vectores AAV de doble unión de glicano
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
EP3049527A4 (en) 2013-09-26 2017-08-16 University of Florida Research Foundation, Inc. Synthetic combinatorial aav capsid library for targeted gene therapy
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
LT3137497T (lt) 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2016049230A1 (en) 2014-09-24 2016-03-31 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
WO2016065001A1 (en) 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
EP3215191B1 (en) * 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
EP4023755B1 (en) 2014-12-12 2023-04-26 CureVac SE Artificial nucleic acid molecules for improved protein expression
CA3255657A1 (en) 2015-02-10 2025-12-01 Genzyme Corporation VARIANT RNAi
CA2977355A1 (en) 2015-02-20 2016-08-25 University Of Iowa Research Foundation Methods and compositions for treating genetic eye diseases
WO2017015102A1 (en) 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Compositions and methods for achieving high levels of transduction in human liver cells
IL314171A (en) 2015-09-28 2024-09-01 Univ Florida Methods and compositions for antibody-evading virus vectors
WO2017066764A2 (en) 2015-10-16 2017-04-20 William Marsh Rice University Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
EP3374494A4 (en) 2015-11-11 2019-05-01 Coda Biotherapeutics, Inc. CRISPR COMPOSITIONS AND METHODS OF USE THEREOF FOR GENE THERAPY
US10240145B2 (en) 2015-11-25 2019-03-26 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
AU2016366549B2 (en) 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
JOP20190269A1 (ar) * 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP2020532961A (ja) 2017-08-15 2020-11-19 インテリア セラピューティクス,インコーポレイテッド メッセンジャーリボ核酸(mRNA)をコードする安定化された核酸
CN108841868A (zh) * 2018-05-31 2018-11-20 康霖生物科技(杭州)有限公司 一种用于中枢神经系统疾病治疗的基因序列构建体
MX2021003995A (es) 2018-10-11 2021-06-23 Ethris Gmbh Plasmido que contiene una secuencia que codifica un arnm con una cola de poli(a) segmentada.
BR112021017744A2 (pt) * 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
CN109971729B (zh) * 2019-04-19 2021-07-16 上海信致医药科技有限公司 一种酶组合物

Similar Documents

Publication Publication Date Title
JP2022549380A5 (cg-RX-API-DMAC7.html)
JP2021106619A5 (cg-RX-API-DMAC7.html)
JP2024009857A5 (cg-RX-API-DMAC7.html)
JP2021087431A5 (cg-RX-API-DMAC7.html)
JP2022516004A5 (cg-RX-API-DMAC7.html)
JP2020527333A5 (cg-RX-API-DMAC7.html)
RU2017115477A (ru) Полинуклеотиды aadc для лечения болезни паркинсона
JP2022504740A5 (cg-RX-API-DMAC7.html)
JP2022508182A5 (cg-RX-API-DMAC7.html)
JP2022535749A5 (cg-RX-API-DMAC7.html)
JP2022529631A5 (cg-RX-API-DMAC7.html)
JP2022542828A5 (cg-RX-API-DMAC7.html)
JP2018522529A5 (cg-RX-API-DMAC7.html)
JP2018510648A5 (cg-RX-API-DMAC7.html)
JP2017509632A5 (cg-RX-API-DMAC7.html)
JP2022551744A5 (cg-RX-API-DMAC7.html)
IL292264B2 (en) aav transfer cassette
JP2024543001A5 (cg-RX-API-DMAC7.html)
JP2023549124A5 (cg-RX-API-DMAC7.html)
JP2023537358A5 (cg-RX-API-DMAC7.html)
JP2023065516A5 (cg-RX-API-DMAC7.html)
JP2024509792A5 (cg-RX-API-DMAC7.html)
JP2023515795A5 (cg-RX-API-DMAC7.html)
JP2025514489A5 (cg-RX-API-DMAC7.html)
JP2022518931A5 (cg-RX-API-DMAC7.html)